ISSN: 2213-1779

Journal Home

Journal Guideline

JACC: Heart Failure Q1 Unclaimed

Elsevier BV Netherlands

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

JACC: Heart Failure is a journal indexed in SJR in Cardiology and Cardiovascular Medicine with an H index of 92. It has an SJR impact factor of 5,352 and it has a best quartile of Q1. It has an SJR impact factor of 5,352.

JACC: Heart Failure focuses its scope in these topics and keywords: heart, failure, prognosis, myocardial, limited, nonobstructive, patients, pediatric, preserved, program, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Cardiology and Cardiovascular Medicine (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

5,352

SJR Impact factor

92

H Index

164

Total Docs (Last Year)

550

Total Docs (3 years)

2723

Total Refs

3196

Total Cites (3 years)

239

Citable Docs (3 years)

5.64

Cites/Doc (2 years)

16.6

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Journal of the American College of Cardiology Q1
Circulation Q1
JAMA Cardiology Q1
Nature Reviews Cardiology Q1
European Journal of Heart Failure Q1

Compare this journals

Aims and Scope

Best articles by citations

The Globalization of Heart Failure Research

A Bayesian Model to Predict Survival After Left Ventricular Assist Device Implantation

Impaired Alveolar Capillary Membrane Diffusion

Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial

Cerebral Hypoperfusion Is Exaggerated With an Upright Posture in Heart Failure

Incidence, Temporal Trends, and Prognostic Impact of Heart Failure Complicating Acute Myocardial Infarction

Measurement to Predict Survival: The Case of Diastolic Pulmonary Gradient

Time for Recognition

G-Protein Beta-3 Subunit Genotype Predicts Enhanced Benefit of Fixed-Dose Isosorbide Dinitrate and Hydralazine

Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population

Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction

Perhexiline, Cardiac Energetics, and Heart Failure

SHOW MORE ARTICLES

Perhexiline: Lessons for Heart Failure Therapeutics *

Light Chains and the Failing Heart

Influenza Vaccination in Patients With Chronic Heart Failure

Is Pump the Answer to Heart Failure With Preserved Ejection Fraction?

The Ongoing Evolution of Optimal Clinical Endpoints for Heart Failure Trials *

Beta-Blockers in Acute Heart Failure

Clinical Outcomes With Use of Erythropoiesis Stimulating Agents in Patients With the HeartMate II Left Ventricular Assist Device

Low-Dose Aspirin in Heart Failure Not Complicated by Atrial Fibrillation

Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure

Hypertension, Obesity, Diabetes, and Heart Failure-Free Survival

Differential Regulation of ANP and BNP in Acute Decompensated Heart Failure: Deficiency of ANP

The Association Between Atrial Fibrillation and Sudden Cardiac Death